Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Sponsor: Genentech, Inc.
Summary
The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.
Official title: A Phase IIa, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Selnoflast in Reducing Vascular Inflammation in Patients With Atherosclerosis at Risk for Major Adverse Cardiac Events
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
162
Start Date
2026-04-30
Completion Date
2028-02-28
Last Updated
2026-04-01
Healthy Volunteers
No
Conditions
Interventions
Selnoflast
Selnoflast will be administered as per the schedule specified in the respective arm.
Placebo
Placebo will be administered as per the schedule specified in the respective arm.
Locations (1)
Alliance Clinical West Hills (Focus Clinical Research)
West Hills, California, United States